Dr. Strosberg on Radiolabeled Somatostatin Analogs in GEP-NETs

Jonathan R. Strosberg, MD
Published: Monday, Feb 12, 2018



Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the development of radiolabeled somatostatin analogs in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Radiolabeled somatostatin analogs have been developed for the past several decades, primarily in Europe. They have been manufactured in hospitals and have treated thousands of patients. The radiolabeled somatostatin analog works through delivery to a somatostatin receptor expressing NET.

The results have been quite good with response rates ranging from about 20% to as high as 50% in pancreatic NETs. Significant median progression-free-survival (PFS) durations have also been reported. Though it took time for the phase III NETTER-1 trial to get regulatory approval, the results showed substantial improvement in PFS as well as strong evidence that overall survival is improved. In a few years, this will be re-examined with mature analysis.
 


Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the development of radiolabeled somatostatin analogs in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Radiolabeled somatostatin analogs have been developed for the past several decades, primarily in Europe. They have been manufactured in hospitals and have treated thousands of patients. The radiolabeled somatostatin analog works through delivery to a somatostatin receptor expressing NET.

The results have been quite good with response rates ranging from about 20% to as high as 50% in pancreatic NETs. Significant median progression-free-survival (PFS) durations have also been reported. Though it took time for the phase III NETTER-1 trial to get regulatory approval, the results showed substantial improvement in PFS as well as strong evidence that overall survival is improved. In a few years, this will be re-examined with mature analysis.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x